SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogelon Mars

Dogelon Mars is generating significant community debate, with investors sharply divided between long-term holders awaiting a potential breakout and skeptics dismissing it as a stagnant project. While proponents highlight its history as an original meme coin and look for catalysts like token burns or ecosystem expansion, others are frustrated by prolonged price stagnation and the perception that it lags behind broader market movements.

Robot Money

Robot Money is generating polarized community interest, with proponents framing it as a high-growth AI-integrated play while skeptics label it as a potential pump-and-dump scheme.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is drawing significant investor interest as it approaches major clinical milestones, including pending Japanese regulatory approvals and upcoming trial readouts that the community views as key value drivers. Investors are actively discussing the company's strong cash position and the unique potential of its Alpha DaRT technology, leading to widespread bullish sentiment and recent analyst price target increases.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is surging as the market reacts to compelling Phase 1 clinical data for its lead oncology asset, TERN-701, which has triggered a flurry of analyst upgrades and heightened institutional interest. While investors are debating the long-term valuation and potential for a buyout, community sentiment remains sharply divided between those riding the massive momentum and skeptics wary of the stock's rapid appreciation based on early-stage trials.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is capturing significant attention as investors speculate on a long-awaited breakout, with the community actively debating the asset's potential as a store of value and comparing its historical consolidation to newer crypto projects. The conversation is driven by intense interest in upcoming regulatory clarity and the asset's technical readiness, while many market participants are bracing for volatility following recent price resistance.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is seeing intense interest as investors weigh the impact of its upcoming first-ever halving against broader decentralized AI infrastructure developments and institutional institutional moves like Grayscale's recent ETF filing. Community sentiment is deeply polarized, with bulls focused on the token's scarcity model and subnet growth, while others express caution regarding the asset's current volatility and heavy dependence on market-wide trends.

Fefe is a memecoin inspired by Matt Furie's book "Mindviscosity," published in 2020.  Follow FEFE, the alter ego of PEPE in the book “Mindviscosity” by Matt Furie.  Fefe is a main character in the book, who is a laid back and carefree frog living in a whimsical world. Fefe's relaxed and adventurous spirit captures the heart of this imaginative universe.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced - TAX: 0/0 This narrative has its roots in a fascinating story.  Join us and become part of the $FEFE community today!

Fefe

The $FEFE community is aggressively pushing the narrative of the token as the official third frog in the Matt Furie universe, positioning it as the spiritual successor and beta play to $PEPE. Investors are actively debating its potential as an undervalued micro-cap while rallying around the project's organic growth and consistent community-led building efforts.

$IMU - The Immunefi token is the central value creation asset powering onchain security.  The next multi-trillion dollar unlock for the onchain economy isn’t capital, it’s security.   Every protocol, DeFi app, and onchain company needs always-on protection to survive.    Powered by $IMU, the Immunefi Magnus platform stands at the center of the next trillion-dollar wave.   As more protocols join Magnus, more researchers contribute, and community members participate, demand for onchain security grows. $IMU is at the heart of this transformation, the asset powering complete security for web3.

Immunefi

Investors are closely tracking Immunefi for its critical role in web3 security, with the community highlighting its significant potential to prevent exploits amid rising crypto thefts. Sentiment remains polarized between long-term proponents betting on its necessary utility and skeptics frustrated by recent price action and consolidation.

Linea is the Layer 2 built from first principles to strengthen Ethereum and the entire ETH economy. Every aspect of its design—from its productive ETH burn mechanics, and capital efficient native yield, to its underlying Ethereum-equivalent zk tech—amplifies the value and utility of Ethereum Mainnet. All of this is backed by the largest ecosystem fund in the space, managed by the most trusted Ethereum builders. With institutional-grade infrastructure, and deep integration across DeFi, Linea is the best chain for ETH capital, where every transaction and every block strengthens Ethereum. Linea is where Ethereum wins.

Linea

Linea is trending due to community buzz surrounding its perceived potential for institutional adoption, specifically driven by discussions about its role in SWIFT pilot programs and its backing by Ethereum co-founder Joe Lubin. Investors are actively debating the token's long-term utility against concerns regarding monthly token unlocks and price volatility.

VeChain, founded in 2015, is a sustainability-focused blockchain driving mass adoption of Web3. Its energy-efficient VeChainThor chain delivers fast, low-cost transactions, making blockchain accessible to millions worldwide. With partnerships including UFC, BCG, and Walmart, and over 2 million active users on VeBetter-powered apps, VeChain is proving real-world impact at scale.  In 2024, the VeChain Renaissance upgrade was launched, introducing Ethereum compatibility, dPoS consensus, and dynamic gas fees. It cut VTHO inflation and introduced StarGate NFT staking, where users lock VET to mint transferable NFTs that earn VTHO, can be delegated to validators, and serve as governance instruments. The upgrade also added new eco node tiers, lowering entry barriers while keeping rewards across higher staking levels.  By combining adoption, upgraded tokenomics, and inclusive staking, VeChain is positioning itself as a leading blockchain where usage, growth, and rewards fuel long-term value creation.

Vechain

VeChain is currently a focal point of intense community polarization, with long-term holders expressing extreme frustration over stagnant price action and the foundation's treasury management, while others double down on accumulation in anticipation of future utility and upcoming network upgrades. Discussion remains dominated by debates over leadership transparency, the impact of high-profile partnerships, and skepticism regarding whether the asset will ever recapture its previous highs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4 Biotech Stocks to Watch for Potential Upside in 2026 

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA in this volatile sector. 

Terns Pharmaceuticals (NASDAQ:TERN) Trading 4.8% Higher - What's Next?

Terns Pharmaceuticals (NASDAQ:TERN) Shares Up 4.8% - Time to Buy...

Terns Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:TERN)

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) saw unusually large options trading activity on Friday. Stock investors purchased 9,767 call options on the stock. This represents an...

Dynamic Technology Lab Private Ltd Grows Stock Position in Terns Pharmaceuticals, Inc. $TERN

Dynamic Technology Lab Private Ltd increased its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 237.2% in the 3rd quarter, according to its most recent disclosure...

DLD Asset Management LP Cuts Stake in Terns Pharmaceuticals, Inc. $TERN

DLD Asset Management LP cut its holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 73.0% in the third quarter, according to the company in its most recent disclosure with the...

Commit To Buy Terns Pharmaceuticals At $30, Earn 34% Using Options

Investors considering a purchase of Terns Pharmaceuticals Inc (Symbol: TERN) shares, but tentative about paying the going market price of $39.66/share, might benefit from considering selling puts...

Viatris Stock to Report Q4 Earnings: What's in the Cards?

VTRS gears up for Q4 results amid Indore import alert, segment revenue pressure and steady margins as shares surge 39.7% in a year.

Terns Pharmaceuticals (NASDAQ:TERN) Raised to "Strong-Buy" at TD Cowen

TD Cowen raised Terns Pharmaceuticals to a "strong-buy" rating in a report on Friday...

ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing

Key PointsORBIMED Advisors LLC reduced stake by 5,409,671 shares in Terns Pharmaceuticals; the estimated trade size is $125.01 million based on quarterly average price...

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Rating of "Moderate Buy" by Brokerages

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the firm, Marketbeat...

Current Price	$46.52
Prev Close	$44.24
Open	$45.50
Dividend Yield	0.00%
50-Day Moving Average	$38.88
Beta	1.05
Avg. Volume	2M
PE Ratio	-45.08

52-Week High	$48.26
52-Week Low	$1.87
Market Capitalization	$4.95B
EPS (Annual)	-$1.12
Price to Book	14.33
Revenue Per Employee	$0.00

TERN
Terns Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TERN News

TERNTerns Pharmaceuticals Inc